ArticleBMC pregnancy and childbirth2025
Association of maternal calprotectin plasma levels with abruption placenta.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gestational-Age Clustering of Recurrent Placental Abruption: A Multicenter Retrospective Descriptive Study.Journal of clinical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe aim of this study was to investigate the relationship between placental abruption and maternal plasma calprotectin levels. MATERIALS AND
methodsThis prospective study included 3865 pregnant women aged 24 weeks' gestation and older who were admitted to Etlik Zübeyde Hanım Women's Health Training and Research Hospital between January 2021 and January 2024. Calprotectin levels were prospectively studied in 33 pregnant women with placental abruption and compared with 48 healthy pregnant women matched for age, parity, body mass index (BMI) and week of gestation. Pregnant women with preeclampsia, gestational diabetes, chorioamnionitis, premature rupture of membranes, preterm labor, corticosteroid use within 7 days, cholestasis, fetal growth restriction, fetal anomalies, systemic infections and multiple pregnancies were excluded from the study. The calprotectin concentration in serum was measured with a Rayto Microplate Reader RT 2100 C (Rayto) using an immunoassay method at 450 wavelengths.
resultsThere was no difference between the groups regarding maternal age, gravidity, parity and BMI. Calprotectin levels were significantly higher in the placental abruption group (p < 0.001). The optimal cutoff value for calprotectin was 91.95 ng/ml (sensitivity 66.67%, specificity 89.58%, the area under the curve (AUC) 0.763, 95% confidence interval 0.649-0.876, and p < 0.001).
conclusionThe results obtained in the present study revealed an association between placental abruption and higher maternal serum calprotectin levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.